While this interaction remains unexplored in endometrial cancer, the mechanistic insights from other systems provide a strong rationale for investigating whether IGF2BP1 similarly regulates PKM2 expression and contributes to metabolic reprogramming and tumor progression in this context. This evidence concerns the gene IGF2BP1 and neoplasm.